Founded in 2012, Medivate Partners focuses on value investing in the cross-border life sciences industry. They have invested in clinical stage biotech companies and contract development manufacturing organizations (CDMOs). With a preference for startups that are 6-10 years old, Medivate Partners typically invests in rounds with 2-3 participants. They have been active in the United States and have had successful exits, particularly in 2016. The firm has a higher than average amount of lead investments and commits exits more frequently compared to other organizations. Medivate Partners typically invests in deals ranging from $10-50 million and participates in less than 2 investment rounds annually.